Research
Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial
The Brief
- Interim results from a prospective trial designed to evaluate the safety of avacopan (Tavneos) in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) were reported from Orlando.
- Coverage describes avacopan as an embattled drug, and the trial was set up specifically to assess its safety.
Why it matters
Avacopan has faced controversy, so a dedicated prospective safety trial gives clinicians and researchers more systematic safety data than prior evidence alone. Full results will be needed to judge the strength of the reported safety findings.
Who’s affected
- clinicians treating ANCA-associated vasculitis
- rheumatologists and nephrologists
- patients with AAV and their caregivers
- #vasculitis
- #avacopan
- #drug safety
- #clinical trial
- #autoimmune disease
(MedPage Today) -- ORLANDO -- Interim results from a prospective trial designed to evaluate safety of avacopan (Tavneos), the embattled drug for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), indicated that the product could...
Timeline
Interim safety results from the dedicated avacopan trial reported by MedPage Today from the ORLANDO meeting
MedPageToday.com - medical news for physicians
Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial